CD33 and myelodysplastic syndrome: PRGN-3006 UltraCAR-T, a chimeric antigen receptor (CAR) T cell therapy targeting CD33, achieved encouraging responses in AML participants, and it is still being evaluated in higher-risk MDS participants (NCT03927261) [136].